ATYR: the balance sheet

MyFinsight

For the quarter ending 2025-09-30, ATYR has $106,652K in assets. $6,150K in cash and cash equivalents.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Balance Sheets	2025-09-30	2025-06-30
Cash and cash equivalents	6,150	17,220
Available-for-sale investments	84,052	63,126
Other receivables	1,042	498
Prepaid expenses	1,770	6,648
Total current assets	93,014	87,492
Restricted cash	2,712	2,878
Property and equipment, net	4,429	4,526
Operating lease, right-of-use assets	5,603	5,678
Financing lease, right-of-use assets	745	894
Other assets	149	66
Total assets	106,652	101,534

Accounts payable	4,064	3,881
Accrued expenses	10,185	10,319
Current portion of operating lease liability	799	769
Current portion of financing lease liability	630	562
Total current liabilities	15,678	15,531
Long-term operating lease liability, net of current portion	10,532	10,745
Long-term financing lease liability, net of current portion	398	602
Common stock, 0.001 par value per share 170,000,000 authorized shares as of september 30, 2025 (unaudited) and december 31, 2024, issued and outstanding shares - 97,986,634 as of september 30, 2025 (unaudited) and 84,038,922 as of december 31, 2024	98	93
Additional paid-in capital	672,339	641,284
Accumulated other comprehensive loss	-1	-75
Accumulated deficit	-592,201	-566,457
Total atyr pharma stockholders equity	80,235	74,845
Noncontrolling interest in pangu biopharma limited	-191	-189
Total stockholders' equity	80,044	74,656
Total liabilities and stockholders equity	106,652	101,534